Drug design and testing: Profiling of antiproliferative agents for cancer therapy using a cell-based methyl-[3H]-thymidine incorporation assay

Methods in Molecular Biology

Volumn 731, Issue , 2011, Pages 451-465

  Griffiths, Matthew ^a   Sundaram, Hardy ^a  

^a NONE

Author keywords

COLO 205 cells; Methyl 3H thymidine incorporation; Mitosis; Proliferation assay; Structure activity relationship

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; AURORA KINASE; DRUG DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; THYMIDINE; TRITIUM;

ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL COUNT; CELL PROLIFERATION; CELL SUSPENSION; CELL VIABILITY; CLINICAL PROTOCOL; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; DRUG DESIGN; DRUG DETERMINATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; METHYL [3H] THYMIDINE INCORPORATION ASSAY; PRIORITY JOURNAL; CELL SURVIVAL; CHEMISTRY; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; METABOLISM; METHODOLOGY; PATHOLOGY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL COUNT; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE; TRITIUM;

EID: 84934435885     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-80-5_36     Document Type: Article

References (8)

1. Friedman, H.M., and Glaubiger, D.L. (1982) Assessment of in vitro drug sensitivity of human tumor cells using thymidine incorporation in a modifed human tumor stem cell. Cancer Res. 42, 4683-4689.
2. Naito, K., Skog, S., Tribukait. B., Andersson. L., Hisazumi. H. (1987) Cell cycle related [3H]-thymidine uptake and its signifcance for the incorporation into DNA. Cell Tissue Kinet. 20, 447-457.
3. Harrington, E.A., Bebbington, D., Moore, J., Rasmussen, R.K., Ajose-Abeogun, A., Nakayama, T., Graham, J.A., Demur, C., Hercend, T., Diu-Hercend, A., Su, M., Golec, J.M., Miller, K.M. (2004). VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases suppresses tumour growth in vivo. Nature Med. 10, 262-267.
4. Hennequin, L.F., Thomas, A.P., Johnstone, C., Stokes, E.S.E., Ple, P.A., Lohmann, J.M., Ogilve, D.J., Dukes, M., Wedge, S.R., Curwen, J.O., Kendrew, J., Lambert-van der Bempt, C. (1999). Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 42, 5369-5389.
5. Ogita, H., Isobe, Y., Takaku, H., Sekine, R., Goto, Y., Misawa, S., Hayashi, H. (2001). Synthesis and structure-activity relationship of diarylamide derivatives as selective inhibitors of the proliferation of human coronary artery smooth muscle cells. Bioorganic & Med. Chem. Lett. 11, 549-551.
6. Boss DS, Beijnen JH and Schellens JH (2009) Clinical experience with aurora kinase inhibitors: a review. Oncologist 14, 780-793.
7. Bebbington, D., Binch, H., Charrier, J.D., Everitt, S., Fraysse, D., Golec, J., Kay, D., Knegtel, R., Mak, C., Mazzei, F., Miller, A., Mortimore, M., O'Donnell, M., Patel, S., Pierard, F., Pinder, J., Pollard, J., Ramaya, S., Robinson, D., Rutherford, A., Studley, J., Westcott, J. (2009) The discovery of the potent aurora inhibitor MK-0457 (VX-680) Bioorg Med Chem Lett. 19, 3586-3592.
8. Zhang, J., Chung, D.Y., Oldenburg, K.R (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67-73.